We are people that truly believe
in the benefits of in-vitro biosynthesis

abcr GmbH with headquarter in Karlsruhe, Germany, is the preferred trading partner of Enzymicals AG. The company has subsidiaries and representatives in Spain, Ireland, Switzerland, France, England, Poland, India, Israel, Japan, Brazil, Russia and USA. As the preferred trading partner abcr GmbH process the entire order procedure for our catalogue products. This includes the preparation of quotations, order confirmations, shipping and invoicing. In any case, customers receive original Enzymicals products and we remain the contact for technical support and all scientific questions.

The Swiss enterprise Solvias is one of the largest independent analytical testing, contract research, development and manufacturing companies. The ligands and specialty unit at Solvias has a proven track record for the efficient and successful development of catalytic processes and with Enzymicals both parties have the perfect combination of complementary services with the aim of providing solutions to challenging chemical transformations. Clients of both parties will benefit from proprietary catalyst portfolios and expertise for catalytic transformations with a suite of related custom synthesis and technology platforms.

For over 15 years ChiralVision has designed, developed and scaled-up immobilized enzyme processes for diverse markets. The immobilization technology based on macroporous polymeric beads to make their application feasible and allow to make innovations in pharma, intermediates, life sciences, cosmetics, food, environment and more. With this collaboration Enzymicals clients can obtain highly professional custom immobilization service and quickly count on first prototypes for evaluation, optionally followed by multiple rounds of optimization which will turn the prototype into a robust reusable catalyst.

By using cutting edge directed enzyme evolution and in silico design methods, Aminoverse engineer enzymes to meet any application requirements. The company look back at a long track record in enzyme development and is a team player for almost 10 years. Together with Enzymicals as technologically complementary partner, the parties are convinced that the best chance to solve an enzyme challenge is to work hand in hand for a common goal. This collaboration takes our value proposition to the next level.

With innovations in computational enzyme design that allows to navigate nature’s complexity and optimize variants to fit your needs, our synergistic partner Candidum is committed to support the discovery of lead candidates and/or the design of improvement strategies on a molecular level. It’s technology of simulation-based metagenome mapping and enzyme engineering hotspot profiles leads to increased efficiency and success rates with simultaneously decreased development timelines. Our alliance enables us to offer complex developments and to bring them to industrial scale.

The CBP in Leuna focuses on the combination of biotechnological processes with chemical processes, and with its pilot scale technical equipment it can close the gap between our laboratories and industrial implementation. By providing the infrastructure and technical facilities as well as a staff of highly qualified experts, it enables Enzymicals to scale-up processes to production-relevant dimensions and also to accelerate process developments. The plant has various scales for fermentation and enzyme-catalyzed reactions up to 10 m³ with a high degree of flexibility.

Chiracon has 20 years of experience in the field of drug synthesis and documentation. As a German company, our partner can reliably offer all services in the field of synthetic drug development for new or generic products with specialization in organic synthesis, scale up and production in a ISO9001/GMP certified environment. This collaboration can provide documentations needed for active pharmaceutical ingredients for clinical trials, and also in order to introduce new APIs to market (ASMF, DMF, CMC, IMPD).

Europe’s flagship in life sciences, provide access to Transform-MinER, an in-silico tool for synthetic analysis, developed at EMBL’s European Bioinformatics Institute, to identify novel high value-added biosynthetic enzyme reactions with relevance to our proprietary product portfolio. The tailored exploration of the chemical biosynthetic space by the use of Transform-MinER’s ligand-based methodology with chemoinformatic fingerprints is beneficial to more efficiently commercialize our technology platform and its biocatalytic potential to fuel our product pipeline.

We work with a range of diverse undisclosed CMOs to enable our clients the commercial supply of our developments and products. No matter whether enzymes or chemical entities. Our proven partners are predominantly located in the EU and the network spans over small, mid-sized and large players in the industry. Together with our collaborators, we expand our service to regulatory affairs, cGMP production and bulk scale supply.